Health

FDA Approves Apellis’ Empaveli (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

DailyTrendDailyTrend
Jul 30, 2025 - 15:00
 0  0
FDA Approves Apellis’ Empaveli (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved Empaveli (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G)...
Read More

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0
DailyTrend
DailyTrend

Related Posts

Why ‘Mankeeping’ Is Turning Women Off

Why ‘Mankeeping’ Is Turning Women Off

DailyTrend Jul 28, 2025  0  0

FDA Approves Sephience (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria

FDA Approves Sephience (sepiapterin) for the Treatment ...

DailyTrend Jul 29, 2025  0  0

Top F.D.A. Official Resigns Under Pressure

Top F.D.A. Official Resigns Under Pressure

DailyTrend Jul 30, 2025  0  0

This Test Tells You More About Your Heart Attack Risk

This Test Tells You More About Your Heart Attack Risk

DailyTrend Jul 28, 2025  0  0

William J. Rutter, Biotech Pioneer of Gene-Based Medicine, Dies at 97

William J. Rutter, Biotech Pioneer of Gene-Based Medici...

DailyTrend Jul 27, 2025  0  0

C.D.C. Ties 85 Cases of THC-Related Symptoms to Wiscons...

DailyTrend Jul 28, 2025  0  0